Accelrys HEOS® Goes Live on BT Cloud Environment

               Accelrys HEOS® Goes Live on BT Cloud Environment

Industry-leading research collaboration workspace within Accelrys Externalized
Collaboration Suite moves to secure, reliable, scalable cloud infrastructure

PR Newswire

BOSTON, April 9, 2013

BOSTON, April 9, 2013 /PRNewswire/ -- Bio-IT World --Accelrys, Inc. (NASDAQ:
ACCL), a leading provider of scientific innovation lifecycle management
software, today announced that the cloud-based Accelrys HEOS^® information
management and collaboration workspace is now live onBT for Life Sciences R&D
cloud platform. BT for Life Sciences R&D provides a secure, reliable and
scalable cloud environment for HEOS users, enabling more efficient and
productive networked collaboration by pharmaceutical research organizations
and their partners. The latest engagement between BT and Accelrys furthers the
relationship on hosting and externalization that has been in place between the
companies since April 2012, while strengthening the enterprise capabilities of
the Accelrys Externalized Collaboration Suite announced today at Bio-IT World.
Combined with the enterprise cloud infrastructure provided by BT, the Accelrys
Externalized Collaboration Suite addresses the needs of research organizations
transitioning to an externalized network research environment.

To view the multimedia assets associated with this release, please click
http://www.prnewswire.com/news-releases/accelrys-heos-goes-live-on-bt-cloud-environment-202040851.html


"With the pharmaceutical industry moving rapidly to a network research model,
organizations are struggling to provide secure, real-time information exchange
and IP protection across externalized networks," said Dr. Matt Hahn, senior
vice president and chief technology officer, Accelrys. "Accelrys and BT
recognize the need for drug discovery research organizations to collaborate
effectively within a secure, reliable, global cloud infrastructure as they
move to this new model."

"BT's robust Life Sciences for R&D cloud service is essential to meeting the
critical business issues raised by externalized network research today," said
Bas Burger, president of Global Pharmaceutical & Chemical for BT Global
Services. "Combining Accelrys HEOS and other Accelrys applications for
externalized research as part of BT for Life Sciences R&D enables scientists
working in pharmaceutical and biotechnology companies, as well as academia and
government, to collaborate effectively in a cloud environment. The platform
is designed to allow customers to comply with the industry's stringent
security, regulatory and compliance requirements."

As part of the Accelrys Externalized Collaboration Suite, Accelrys HEOS is a
proven Software-as-a-Service (SaaS) workspace that accelerates collaborative
drug discovery. The system provides secure, real-time cloud access to data
about such things as chemical registration, biological assay results,
computational and visual analytics, safety assessment and pharmacokinetics
data, and other project information. This material can be accessed with
greatly reduced effort and IT overhead. Accelrys HEOS enables pharmaceutical
and biotechnology companies, contract research organizations, academic
institutions and other partnering research organizations to access critical
information, share results and make informed decisions in a timely manner with
all IP stored in a secure, project-specific information warehouse.

BT for Life Sciences R&D was developed as a secure and segregated platform,
using BT Cloud Compute. It allows scientists to construct and orchestrate in
silico workflows and data pipelines so that new pharmaceutical targets and
drug candidates can be identified. This platform, launched at BioIT World
2012, enables research scientists to create global project groups and
collaborate using social media tools. This ecosystem allows them to securely
upload documents, share results and communicate via IM, voice, video or chat.
They can also analyze results in an environment that segments data and uses
qualified hardware components and workflows specific to the pharmaceutical
industry.

Refer to the Accelrys website for more information on Accelrys HEOS and the
Accelrys Externalized Collaboration Suite.

About Accelrys, Inc.
Accelrys, Inc. (NASDAQ: ACCL), a leading provider of scientific innovation
lifecycle management software, supports industries and organizations that rely
on scientific innovation to differentiate themselves. The industry-leading
Accelrys Enterprise Platform provides a broad and flexible scientific solution
optimized to integrate the diversity of science, experimental processes and
information requirements across the research, development, process scale-up
and early manufacturing phases of product development. By incorporating
capabilities in applications for modeling and simulation, enterprise lab
management, workflow and automation, and data management and informatics,
Accelrys enables scientific innovators to access, organize, analyze and share
data in unprecedented ways, ultimately enhancing innovation, improving
productivity and compliance, reducing costs and speeding time from lab to
market.

Accelrys solutions are used by more than 1,300 companies in the
pharmaceutical, biotechnology, energy, chemicals, aerospace, consumer packaged
goods and industrial products industries. Headquartered in San Diego,
California, USA, Accelrys employs more than 200 full-time PhD scientists. For
more information about Accelrys, visit www.accelrys.com.

About BT
BT is one of the world's leading providers of communications services and
solutions, serving customers in more than 170 countries. Its principal
activities include the provision of networked IT services globally; local,
national and international telecommunications services to its customers for
use at home, at work and on the move; broadband and internet products and
services and converged fixed/mobile products and services. BT consists
principally of four lines of business: BT Global Services, BT Retail, BT
Wholesale and Openreach.

In the year ended 31 March 2012, BT Group's revenue was £18,897m with profit
before taxation of £2,445m.

British Telecommunications plc (BT) is a wholly-owned subsidiary of BT Group
plc and encompasses virtually all businesses and assets of the BT Group. BT
Group plc is listed on stock exchanges in London and New York.

For more information, visit www.btplc.com

Related Links
Accelrys Website
Follow Accelrys on Twitter
Friend Accelrys on Facebook
Accelrys' YouTube Channel
Connect with Accelrys on LinkedIn

SOURCE Accelrys, Inc.

Website: http://www.accelrys.com
Contact: Susan Thomas, Racepoint Group for Accelrys, 619-540-9195,
sthomas@racepointgroup.com; Kris Kozamchak, Head of PR and Corporate Relations
U.S., BT, 972-310-9055, kris.kozamchak@bt.com
 
Press spacebar to pause and continue. Press esc to stop.